Yaohai Bio-Pharma has been awarded the 2025 Best CDMO for Customer Satisfaction, recognizing its excellence in CRDMO services, global partnerships, and innovation in biologics development.
August 1, 2025 — Yaohai Bio-Pharma has been honored with the “2025 Best Client Satisfaction CDMO” award at the TOP101 Pharma Industry Awards Ceremony, held during the annual CMC Pharmaceutical Industry Expo. Jointly hosted by the expo and a major pharma innovation platform, this award recognizes Yaohai’s strong client reputation, robust CRDMO service framework, and commitment to quality and compliance.
A Decade of CRDMO Excellence in Microbial Expression Systems
For over ten years, Yaohai Bio-Pharma has remained focused on advancing microbial expression system-based solutions for biologics. The company’s mission—setting global standards, accelerating drug development, and enabling healthier lives—guides every project it delivers.
Yaohai provides end-to-end CRDMO (Contract Research, Development, and Manufacturing Organization) services that span from early-stage R&D to large-scale commercial manufacturing. Areas of expertise include:
- Recombinant proteins and peptides
- Nucleic acid therapeutics
- Nanobodies
- Plasmid DNA
- Novel recombinant vaccines
With deep capabilities in genetic engineering, high-density fermentation, precision purification, and quality system integration, Yaohai has successfully executed over 200 CMC (Chemistry, Manufacturing, and Controls) projects. Its ability to navigate complex regulatory pathways and meet global quality standards has earned Yaohai strong trust within the industry.
Globally Connected, Client-Focused
Yaohai Bio-Pharma collaborates with top global pharmaceutical and biotech companies, providing customized solutions that prioritize quality, speed, and flexibility. Known for its scientific depth and operational excellence, Yaohai is considered a strategic CRDMO partner by innovators worldwide.
Headquartered in China, the company delivers high-quality, lifecycle-focused services across Australia, Europe, and APAC. With deep scientific expertise and a proven track record of CMC success, Yaohai empowers biopharma innovators to bring advanced therapies to market with confidence.
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with over a decade of experience in microbial expression systems. Focused on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and novel vaccines, Yaohai provides full-lifecycle solutions from R&D to commercial manufacturing. The company is committed to building an open and integrated CRO/CDMO/MAH platform that drives innovation from discovery to commercialization, serving as a trusted partner to global biopharma companies.
